Pfizer Zyrtec-D promotions
Executive Summary
Professional sales aid and product website for Zyrtec-D (certirizine/pseudoephedrine) fail to include contraindications and warnings regarding the antihistamine's pseudoephedrine component, April 22 1FDA ad division letter says. Associate Commissioner Peter Pitts recently pointed to Pfizer's website as a model for internet promotion (2"The Pink Sheet" April 5, 2004, p. 18)...
You may also be interested in...
Decline In Ad Letters Does Not Signal Leniency By FDA, Agency Says
Although FDA is issuing fewer warning letters, those issued are more likely to signal a potential enforcement action, FDA Associate Commissioner Peter Pitts suggested during the DTC National Conference & Expo in Boston March 30
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.